Table 1.

The demographic and clinicopathological characteristics of patient

Variable	Total (n = 135)
Baseline characteristics
Age, median (IQR), year	55.00 ± 9.73
Gender
Male     Female	74.1% (100/135) 25.9% (35/135)
ECOG status
0     1	8.1% (11/135) 91.9% (124/135)
Education
Illiterate/primary school     High school/undergraduate	26.7% (36/135) 73.3% (99/135)
Socioeconomic status
Low to moderate income     High income	78.5% (106/135) 21.5% (29/135)
Smoking
Yes     No	30.4% (41/135) 69.6% (94/135)
Alcohol
Yes     No	25.9% (35/135) 74.1% (100/135)
Clinicopathological parameters
Location
Colon     Rectum	26.7% (36/135) 73.3% (99/135)
T stage (pT)
T1     T2     T3     T4	0.7% (1/135) 15.6% (21/135) 55.6% (75/135) 28.1% (38/135)
N stage (pN)
N0     N1     N2	55.6% (75/135) 29.6% (40/135) 14.8% (20/135)
Tumor size (IQR) cm	3.80 ± 1.30
Differentiation
Well     Medium     Poor	9.6% (13/135) 63.7% (86/135) 26.7% (36/135)
Blood NLR (IQR)	2.41 ± 1.75
Serum CEA
Normal     Elevated	73.3% (99/135) 26.7% (36/135)
Serum CA19-9
Normal     Elevated	84.4% (114/135) 15.6% (21/135)
Operation
Laparoscopic     Conversion to laparotomy	86.7% (117/135) 13.3% (18/135)
Postoperative parameters
Complication
No     Grades 1 and 2     ≥ Grade 3	86.7% (117/135) 8.9% (12/135) 4.4% (6/135)
Hospital stay, median, days	16 ± 4.7
Time between AC and operation, median, days	28 ± 14.9
AC within 4 weeks
Yes     No	59.3% (80/135) 40.7% (55/135)
AC within 8 weeks
Yes     No	94.1% (127/135) 5.9% (8/135)
AC regimen
CapeOX     SOX     Capecitabine/S-1     FOLFOX6     Other	83.0% (112/135) 8.1% (11/135) 3.7% (5/135) 3.0% (4/135) 2.2% (3/135)
AC complete rate
Yes     No	73.3% (99/135) 26.7% (36/135)

CI, confidence interval; IQR, interquartile range; ECOG, Eastern Cooperative Oncology group; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen; NLR, neutrophil to lymphocyte ratio; AC, adjuvant chemotherapy